CCDC88A: A Potential Drug Target and Biomarker for G伪-Interacting Vesicle-Associated Protein

Target Name: CCDC88A

NCBI ID: G55704

CCDC88A

Other Name(s): G{alpha}-interacting vesicle-associated protein | APE | PEHOL | g alpha-interacting vesicle-associated protein | Coiled-coil domain-containing protein 88A | GRDN_HUMAN | KIAA1212 | GRDN | Girdin | Akt phosphorylation enhancer | GIRDIN | HkRP1 | PEHO | CCDC88A variant 2 | Girders of actin filament | GIV | AKT-phosphorylation enhancer | Coiled-coil domain containing 88A, transcript variant 2 | Girdin (isoform 2) | G alpha-interacting vesicle-associated protein | coiled-coil domain containing 88A | girders of actin filaments | Hook-related protein 1

CCDC88A: A Potential Drug Target and Biomarker for G伪-Interacting Vesicle-Associated Protein

G伪-interacting vesicle-associated protein (VAP) is a protein that plays a crucial role in various cellular processes, including cell signaling, intracellular transport, and cytoskeletal organization. CCDC88A, a member of the G伪 superfamily, is a 21-kDa protein that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases.

CDC88A is a unique protein that is expressed in various tissues and cell types, including neurons, astrocytes, pericytes, and endothelial cells. It is involved in several cellular processes, including the regulation of cell signaling pathways, such as the cAMP/cGMP signaling pathway, and the regulation of intracellular transport, such as the transport of neurotransmitters and ion channels.

CDC88A functions as a negative regulator of the RhoA GTPase, which is a key enzyme involved in the regulation of cell signaling pathways. RhoA GTPase is a protein that plays a crucial role in the regulation of various cellular processes, including cell signaling, cytoskeletal organization, and intracellular transport. The RhoA GTPase is activated by various agonists, including src, a protein that is involved in the regulation of cell signaling pathways.

CDC88A is also involved in the regulation of the actinin complex, which is a protein that is involved in cytoskeletal organization and the regulation of cell signaling pathways. The actinin complex is a protein that is composed of several subunits, including Myosin, actinin-1, and actinin-2. Myosin is a protein that is involved in the regulation of muscle contractions, while actinin-1 and actinin-2 are involved in the regulation of cytoskeletal organization and the regulation of cell signaling pathways.

CDC88A is also involved in the regulation of the Src/FAK-associated signaling pathway, which is involved in the regulation of cell signaling pathways. The Src/FAK-associated signaling pathway is a protein that is involved in the regulation of cell signaling pathways, including the regulation of cell growth, differentiation, and survival.

CDC88A is a 21-kDa protein that is composed of several subunits, including a 120-kDa catalytic subunit and several smaller subunits that are involved in the regulation of various cellular processes. It is expressed in various tissues and cell types, including neurons, astrocytes, pericytes, and endothelial cells.

CDC88A has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Several studies have shown that blocking the function of CDC88A can lead to the inhibition of various cellular processes, including cell signaling, intracellular transport, and cytoskeletal organization.

One of the potential benefits of targeting CDC88A is that it can be used as a biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. For example, several studies have shown that targeting CDC88A can lead to the inhibition of various cellular processes, including cell signaling, intracellular transport, and cytoskeletal organization. This can lead to the inhibition of the growth, migration, and survival of cancer cells, as well as the exacerbation of neurodegenerative disorders and cardiovascular diseases.

Another potential benefit of targeting CDC88A is that it can be used as a drug target for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Several studies have shown that blocking the function of CDC88A can lead to the inhibition of various cellular processes, including cell signaling, intracellular transport, and cytoskeletal organization. This can lead to the inhibition of the growth, migration, and survival of cancer cells, as well as the exacerbation of neurodegenerative disorders and cardiovascular diseases.

Conclusion

In conclusion, CDC88A is a protein that is involved in various cellular processes, including the regulation of cell signaling pathways, intracellular transport, and cytoskeletal organization. It is a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and cardiovascular diseases. Further research is needed to fully understand the function of CDC88A and its potential as a drug target and biomarker.

Protein Name: Coiled-coil Domain Containing 88A

Functions: Bifunctional modulator of guanine nucleotide-binding proteins (G proteins) (PubMed:19211784, PubMed:27621449). Acts as a non-receptor guanine nucleotide exchange factor which binds to and activates guanine nucleotide-binding protein G(i) alpha subunits (PubMed:19211784, PubMed:21954290, PubMed:23509302, PubMed:25187647). Also acts as a guanine nucleotide dissociation inhibitor for guanine nucleotide-binding protein G(s) subunit alpha GNAS (PubMed:27621449). Essential for cell migration (PubMed:20462955, PubMed:16139227, PubMed:19211784, PubMed:21954290). Interacts in complex with G(i) alpha subunits with the EGFR receptor, retaining EGFR at the cell membrane following ligand stimulation and promoting EGFR signaling which triggers cell migration (PubMed:20462955). Binding to Gi-alpha subunits displaces the beta and gamma subunits from the heterotrimeric G-protein complex which enhances phosphoinositide 3-kinase (PI3K)-dependent phosphorylation and kinase activity of AKT1/PKB (PubMed:19211784). Phosphorylation of AKT1/PKB induces the phosphorylation of downstream effectors GSK3 and FOXO1/FKHR, and regulates DNA replication and cell proliferation (By similarity). Binds in its tyrosine-phosphorylated form to the phosphatidylinositol 3-kinase (PI3K) regulatory subunit PIK3R1 which enables recruitment of PIK3R1 to the EGFR receptor, enhancing PI3K activity and cell migration (PubMed:21954290). Plays a role as a key modulator of the AKT-mTOR signaling pathway, controlling the tempo of the process of newborn neuron integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation (By similarity). Inhibition of G(s) subunit alpha GNAS leads to reduced cellular levels of cAMP and suppression of cell proliferation (PubMed:27621449). Essential for the integrity of the actin cytoskeleton (PubMed:16139227, PubMed:19211784). Required for formation of actin stress fibers and lamellipodia (PubMed:15882442). May be involved in membrane sorting in the early endosome (PubMed:15882442). Plays a role in ciliogenesis and cilium morphology and positioning and this may partly be through regulation of the localization of scaffolding protein CROCC/Rootletin (PubMed:27623382)

The "CCDC88A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCDC88A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets